110 related articles for article (PubMed ID: 10527649)
1. Open questions on bioequivalence: some problems and some solutions.
Marzo A
Pharmacol Res; 1999 Oct; 40(4):357-68. PubMed ID: 10527649
[TBL] [Abstract][Full Text] [Related]
2. Critical considerations into the new EMA guideline on bioequivalence.
Marzo A; Fontana E
Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
[TBL] [Abstract][Full Text] [Related]
3. Acceptable and unacceptable procedures in bioavailability and bioequivalence trials.
Marzo A; Ceppi Monti N
Pharmacol Res; 1998 Nov; 38(5):401-4. PubMed ID: 9806821
[TBL] [Abstract][Full Text] [Related]
4. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
Marzo A; Balant LP
Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
[TBL] [Abstract][Full Text] [Related]
6. Open questions in bioequivalence.
Marzo A
Pharmacol Res; 1995 Oct; 32(4):237-40. PubMed ID: 8866840
[TBL] [Abstract][Full Text] [Related]
7. Open questions on bioequivalence: an updated reappraisal.
Marzo A
Curr Clin Pharmacol; 2007 May; 2(2):179-89. PubMed ID: 18690864
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
Chen ML; Lee SC; Ng MJ; Schuirmann DJ; Lesko LJ; Williams RL
Clin Pharmacol Ther; 2000 Nov; 68(5):510-21. PubMed ID: 11103754
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
Rajaram L; Roy SK; Skerjanec A
Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
[TBL] [Abstract][Full Text] [Related]
10. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
[TBL] [Abstract][Full Text] [Related]
11. Current regulatory approaches of bioequivalence testing.
Karalis V; Macheras P
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
[TBL] [Abstract][Full Text] [Related]
12. Assessing bioequivalence using genomic data.
Chow SC; Shao J; Li L
J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
[TBL] [Abstract][Full Text] [Related]
13. Assessing the bioequivalence of analogues of endogenous substances ('endogenous drugs'): considerations to optimize study design.
Dissanayake S
Br J Clin Pharmacol; 2010 Mar; 69(3):238-44. PubMed ID: 20233194
[TBL] [Abstract][Full Text] [Related]
14. The new European Medicines Agency guideline on the investigation of bioequivalence.
Morais JA; Lobato Mdo R
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
[TBL] [Abstract][Full Text] [Related]
15. [What model for pharmacokinetic analysis of tissue distribution and bioequivalence?].
Marzo A; Monti NC
Boll Chim Farm; 1998 Mar; 137(3):69-73. PubMed ID: 9611844
[TBL] [Abstract][Full Text] [Related]
16. New questions regarding bioequivalence of levothyroxine preparations: a clinician's response.
Green WL
AAPS J; 2005 Mar; 7(1):E54-8. PubMed ID: 16146330
[TBL] [Abstract][Full Text] [Related]
17. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics.
Fernández-Teruel C; Gonzalez-Alvarez I; Navarro-Fontestad C; García-Arieta A; Bermejo M; Casabó VG
Eur J Pharm Sci; 2009 Jan; 36(1):147-56. PubMed ID: 19038335
[TBL] [Abstract][Full Text] [Related]
18. An area correction method to reduce intrasubject variability in bioequivalence studies.
Abdallah HY
J Pharm Pharm Sci; 1998; 1(2):60-5. PubMed ID: 10945919
[TBL] [Abstract][Full Text] [Related]
19. Analysis of pooled plasma samples as a predictor for proving bioequivalence of drugs with a long elimination half-life. The example of phenprocoumon.
Gatchev E; Thyroff-Friesinger U; Bakracheva N; Kirkov V; Koytchev R; van der Meer MJ
Arzneimittelforschung; 2004; 54(10):685-9. PubMed ID: 15553109
[TBL] [Abstract][Full Text] [Related]
20. [Harmonization of testing drugs for bioequivalence: problems and possible solutions].
Zherdev VP; Kolyvanov GB; Litvin AA; Sariev AK
Eksp Klin Farmakol; 2003; 66(2):60-4. PubMed ID: 12962051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
